CN100497591C - Engineered bacteria Pichia pastoris for high yield of insulinotropic hormone and its construction method - Google Patents
Engineered bacteria Pichia pastoris for high yield of insulinotropic hormone and its construction method Download PDFInfo
- Publication number
- CN100497591C CN100497591C CNB2005100135141A CN200510013514A CN100497591C CN 100497591 C CN100497591 C CN 100497591C CN B2005100135141 A CNB2005100135141 A CN B2005100135141A CN 200510013514 A CN200510013514 A CN 200510013514A CN 100497591 C CN100497591 C CN 100497591C
- Authority
- CN
- China
- Prior art keywords
- glp
- peptide
- glucagon
- pichia spp
- transformant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention discloses a Pichia pastoris engineering bacterium and building method of high-production insulinotropic hormone, which is characterized by the following: building pPIC9GLP-1 as P.pastoris expressing carrier firstly; transmitting the lineated P.pastoris expressing carrier into GS115 to produce the product; keeping long time activity for Pichia pastoris.
Description
Technical field
The present invention relates to a kind of high yield of insulinotropic hormone Pichia yeast engineering (Pichiapastoris) and construction process thereof, belong to the molecular biosciences field.
Background technology
The chemical name of hGLP-1 (GLP-1) is glucagon-like-peptide-1 (glucagon-like peptide-1), is a kind of remarkable enhanced material of insulin secretion that makes glucose induction by the special acceptor interaction with the beta Cell of islet surface.Studies confirm that GLP-1 can stimulate insulin secretion, and the effect of the high more GLP-1 of blood sugar is strong more; But when returning to normal value as blood sugar concentration, just not continuation effect again of GLP-1, thereby can not produce the hypoglycemia phenomenon; In addition, GLP-1 also reduces the islet cells damage simultaneously, improve the islet cells structure, the repairing islet cells function, improve the islet cells vigor and prolong its life-span, suppress that pancreas rises the plain release of sugar, regulation and control pancreatic beta cell specific gene is expressed and improve glucose running and metabolism by this gene regulating, improve the β cell to the reactive of glucose and reduce appetite and suppress the emptying etc. of stomach.Therefore present GLP-1 is considered to can be used for fundamentally treating the material of diabetes, and is significant for treatment of diabetes.
It is that constructing host cell is produced the engineering bacteria of GLP-1 and is used for liquid fermentation and culture with intestinal bacteria that Chinese patent (CN1363654A) discloses a kind of, generation and accumulation contain the inclusion body of GLP-1 (7-36), separation and purification by cytoclasis and inclusion body obtains fusion rotein, and the purifying that passes through fusion rotein cracking and GLP-1 (7-36) again obtains product.
Domesticly there is people such as bibliographical information Zhang Zhi treasure to utilize intestinal bacteria to produce hGLP-1[Chinese biological chemistry and molecular biosciences journal, 2002,2,18 (1): 5-8].People such as Zhang Zhi treasure adopt 6 oligonucleotide fragments of the synthetic hGLP-1cDNA of phosphorous acid diester method, be spliced into complete hGLP-1cDNA, construction recombination plasmid transformed into escherichia coli BL21 (DE3) obtains expression strain, and high density fermentation is cultivated, and purifying obtains gst fusion protein.The content of GST-rhGLP-1 recombinant protein is 2.1g/L behind the purifying.
Foreign literature is reported, people such as Egel-Mitani utilize yeast saccharomyces cerevisiae (S.cerevisiae) to produce small peptide (comprising) GLP-1, GLP-2, GRPP etc., wherein the fermentation yield of GLP-1 can reach 34.3mg/L in the yeast saccharomyces cerevisiae of wild-type, (US6110703/Novo Nordisk/S, 2000.08.29).
Summary of the invention
The purpose of this invention is to provide a kind of pichia spp (Pichia pastoris) GLP-1 high-yielding engineering bacterial strain and construction process thereof, in the hope of utilizing this high yield engineering bacteria fermentative production hGLP-1 (GLP-1) on a large scale.
The present invention utilizes the pichia spp eukaryotic expression system to produce GLP-1, its expression product albumen can not produce high resistance originality, expression amount is high and can be secreted into outside the born of the same parents, when obtaining high yield, overcome the shortcoming that products therefrom when producing GLP-1 with escherichia expression system is difficult for purifying and is easy to generate immunogenicity, be particularly suitable for the medical treatment purposes with the product of bacterial strain production of the present invention.
GLP-1 superior strain of the present invention can reach 100mg/L through identifying GLP-1 output, and the yeast saccharomyces cerevisiae that utilizes that is higher than aforementioned foreign literature report is far away produced GLP-1.
Still there is not the report that makes up pichia spp (Pichia pastoris) GLP-1 engineering bacteria at present both at home and abroad.
The object of the invention is achieved through the following technical solutions:
1) make up pichia spp (P.pastoris) expression vector pPIC9GLP-1:
According to the sequence characteristic of yeast expression vector pPIC9 plasmid multiple clone site, design upstream primer and downstream primer; The GLP-1 that clones directly is connected into T-vector obtains pMDGLP-1, cut with Smal I and Not I enzyme and obtain the GLP-1 gene fragment; Plasmid pPIC9 cuts the back with the XhoI enzyme and mends flat cohesive end; Cut with Not I enzyme again, reclaim big fragment; The GLP-1 gene fragment is connected by the T4DNA ligase enzyme with the big fragment of pPIC9, thereby the screening positive transformant is finished the structure of yeast expression vector pPIC9GLP-1.
2) make up pichia spp GLP-1 and produce bacterial strain:
Recombinant plasmid pPIC9GLP-1 cuts with the SacI enzyme and makes it linearizing, transforms Pichi strain GS115 competent cell with the Lithium Acetate conversion method again; Cultivated two days on the MD substratum, the picking positive transformant obtains pichia spp GLP-1 and produces bacterial strain.
3) screening pichia spp GLP-1 superior strain:
By methods such as PCR, Southern hybridization and Western blot transformant is carried out Molecular Detection, conclusive evidence GLP-1 gene has been incorporated into pichia spp genome and correct the expression; With each transformant cell inoculation in the BMGY liquid nutrient medium, 30 ℃ of shaking culture 40～48 hours, 250r/min, the centrifugal supernatant of abandoning changes the BMMY liquid nutrient medium under the aseptic condition; In inducing process, added an amount of methyl alcohol its final concentration is maintained near 0.75% in per 24 hours; Cultivate the supernatant substratum of centrifugal each transformant of collection after 60 hours; Detect the secreting, expressing output of the GLP-1 of transformant with Tricine SDS-PAGE protein electrophorese and density scan method, filter out pichia spp GLP-1 superior strain.
When clone GLP-1 gene fragment, the upstream and downstream primer is selected following scheme:
Upstream primer cccgggcaaa agacattctg agggaac
Downstream primer gcggccgctta acggccatct acg
Advantage of the present invention and characteristics are:
A, bacterial strain GLP-1 expression amount of the present invention is high and can be secreted into outside the born of the same parents, easily purifying.The present invention is a pichia spp eucaryon table
Reach system, different with prokaryotic expression system, it can carry out the modification after a series of translations, and it can use potent alcohol oxidase (AOX1) promotor, realizes efficiently expressing of foreign gene under methanol induction.
The GLP-1 that b, bacterial strain of the present invention are produced has been eliminated tryptic restriction enzyme site on aminoacid sequence, be difficult for can not being occurred the problem of inactivation when making oral preparations by trypsin degradation.General protein-based oral entering after the stomach and intestine, great majority all can be degraded by enzymes such as stomach en-and trypsinase, the GLP-1 of bacterial strain production of the present invention undergos mutation on its gene order by the mode of point mutation, has eliminated tryptic restriction enzyme site at last on aminoacid sequence.These characteristics of product are a kind of Gospels for the patient of diabetes, and especially for type i diabetes, because of its treatment is to rely on the continuous supplementation with insulin of drug administration by injection always, and the long term injections medicine has brought a lot of inconvenience and misery to patient.
The GLP-1 that c, bacterial strain of the present invention are produced survival time more natural GLP-1 in vivo is long.Natural hGLP-1 (GLP-1) can be degraded and inactivation by intravital specificity pepx IV (DPP IV) in vivo very soon, and the GLP-1 that bacterial strain of the present invention is produced has been eliminated pepx IV in the hGLP-1 (DPP IV) restriction enzyme site dexterously, can guarantee that product keeps the functionally active of long period in vivo, has improved the treatment of diabetes effect.
The expression product albumen of the GLP-1 Pichia yeast engineering that d, the present invention make up can not produce immunogenicity, and product is particularly suitable for therepic use.
Description of drawings
GLP-1 aminoacid sequence that the bacterial strain that Fig. 1, the present invention make up is produced and the contrast of natural GLP-1 aminoacid sequence
The technological line of the pichia pastoris engineered strain of Fig. 2, screening high yield of insulinotropic hormone
Embodiment
With embodiment the present invention is described below, but does not limit the present invention.
Embodiment 1
1) make up pichia spp (P.pastoris) expression vector pPIC9GLP-1:
According to the sequence characteristic of pPIC9 plasmid multiple clone site, select upstream primer cccgggcaaa agacattctg agggaac, downstream primer gcggccgctta acggccatct acg; The GLP-1 that clones directly is connected into T-vector obtains pMDGLP-1, cut with Smal I and Not I enzyme and obtain the GLP-1 gene fragment; Plasmid pPIC9 cuts with the XhoI enzyme, mends flat cohesive end then, cuts with the NotI enzyme again, reclaims big fragment; The GLP-1 gene fragment is connected the screening positive transformant by the T4DNA ligase enzyme with the big fragment of pPIC9.
20 μ LPCR reaction systems
10×Buffer 2.0
Upstream primer 0.5
Downstream primer 0.5
dNTP 0.4
Taq archaeal dna polymerase 0.7
Template 0.3
Aseptic double-distilled water 15.6
Totally 20 μ L
94 ℃ of 10min of the pre-sex change of response procedures
94 ℃ of 55sec of sex change
33 circulations of 53 ℃ of 55sec of annealing
Extend 72 ℃ of 30sec
Extend 72 ℃ of 5min
4 ℃ of insulations
2) make up pichia spp GLP-1 and produce bacterial strain:
Recombinant plasmid pPIC9GLP-1 cuts with the SacI enzyme and makes it linearizing, adopts the Lithium Acetate conversion method to transform Pichi strain GS115 competent cell afterwards.Cultivated two days on the MD substratum, the picking positive transformant obtains pichia spp GLP-1 and produces bacterial strain.
3) screening pichia spp GLP-1 superior strain:
By methods such as PCR, Southern hybridization and Western blot transformant is carried out Molecular Detection, conclusive evidence GLP-1 gene has been incorporated into genome and correct the expression; With each transformant pichia spp cell inoculation in the BMGY liquid nutrient medium, 30 ℃ of shaking culture 40～48 hours, 250r/min, the centrifugal supernatant of abandoning changes the BMMY liquid nutrient medium under the aseptic condition.In inducing process, added an amount of methyl alcohol its final concentration is maintained near 0.75% in per 24 hours.Cultivate the supernatant substratum of centrifugal each transformant of collection after 60 hours.Detect the secreting, expressing output of the GLP-1 of transformant with Tricine SDS-PAGE protein electrophorese and density scan method, filter out pichia spp GLP-1 superior strain.
Embodiment 2
1) fermentation culture of pichia spp
With each transformant pichia spp cell inoculation in 5ml BMGY liquid nutrient medium, 30 ℃ of shaking culture 40～48 hours, the centrifugal supernatant of abandoning under the aseptic condition changes 10ml BMMY liquid nutrient medium into.In inducing process, added an amount of methyl alcohol and make its final concentration maintain about 0.75% in per 24 hours.Cultivate centrifugal collection supernatant after 60 hours, not adding methanol induction is blank.
The prescription of BMGY and BMMY substratum:
1％ yeast?extract
2％ peptone
100 mM?potassium?phosphate，pH6.0
1.34％?YNB
4x10
-5％?biotin
1％?glycerol?or?0.5％?methanol
2) collecting precipitation of target protein and electrophoresis detection
Centrifugal 10 minutes of fermented liquid 12000X, the supernatant liquor that obtains comes precipitating proteins with the 100%TCA of ammonium sulfate or 1/10 volume, adopts Tricine-SDS-PAGE protein electrophorese to determine the expression of target protein then.
3) evaluation of high yield pichia pastoris engineered strain
By the density scan method electrophoretic band is carried out scanning analysis, to determine the secreting, expressing amount of each positive transformant, filter out the engineering strain of pichia spp high yield of insulinotropic hormone, the output of gained this project bacterium fermentative production GLP-1 can reach 100mg/L.
Claims (3)
1, the construction process of a kind of product glucagon-like-peptide-1 (GLP-1) Pichia yeast engineering is characterized in that comprising:
A) make up pichia spp (P.pastoris) expression vector pPIC9GLP-1:
Sequence characteristic according to yeast expression vector pPIC9 plasmid multiple clone site, design upstream primer and downstream primer, glucagon-like-peptide-1 (GLP-1) gene of cloning directly is connected into the T-carrier, and (T-vector) obtain pMDGLP-1 cuts with Smal I and Not I enzyme and obtains glucagon-like-peptide-1 (GLP-1) gene fragment; Plasmid pPIC9 cuts the back with XhoI I enzyme and mends flat cohesive end; Cut with Not I enzyme again, reclaim big fragment; Glucagon-like-peptide-1 (GLP-1) gene fragment is connected by the T4DNA ligase enzyme with the big fragment of pPIC9, thereby the screening positive transformant is finished the structure of yeast expression vector pPIC9GLP-1;
B) make up pichia spp glucagon-like-peptide-1 (GLP-1) and produce bacterial strain:
Recombinant plasmid pPIC9GLP-1 cuts with the SacI enzyme and makes it linearizing, transforms Pichi strain GS115 competent cell with the Lithium Acetate conversion method again; Cultivated two days on the MD substratum, the picking positive transformant obtains pichia spp glucagon-like-peptide-1 (GLP-1) and produces bacterial strain;
C) screening pichia spp glucagon-like-peptide-1 (GLP-1) is produced bacterial strain:
By PCR, Southern hybridization and Western blot method transformant is carried out Molecular Detection, conclusive evidence glucagon-like-peptide-1 (GLP-1) gene has been incorporated into genome and correct the expression; With each transformant pichia spp cell inoculation in the BMGY liquid nutrient medium, 30 ℃ of shaking culture 40～48 hours, 250 rev/mins, the centrifugal supernatant of abandoning changes the BMMY liquid nutrient medium under the aseptic condition; In inducing process, added an amount of methyl alcohol and make its final concentration maintain 0.75% in per 24 hours; Cultivate the supernatant substratum of centrifugal each transformant of collection after 60 hours; Detect the secreting, expressing output of the glucagon-like-peptide-1 (GLP-1) of transformant with Tricine SDS-PAGE protein electrophorese and density scan method, filter out pichia spp glucagon-like-peptide-1 (GLP-1) and produce bacterial strain.
2, according to the construction process of the described engineering bacteria of claim 1, the upstream primer and the downstream primer that are adopted when it is characterized in that cloning glucagon-like-peptide-1 (GLP-1) gene fragment are respectively:
Upstream primer cccgggcaaa agacattctg agggaac
Downstream primer gcggccgctta acggccatct acg.
3, according to the pichia spp glucagon-like-peptide-1 production engineering bacterial strain of claim 1 or the preparation of 2 described methods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100135141A CN100497591C (en) | 2005-05-16 | 2005-05-16 | Engineered bacteria Pichia pastoris for high yield of insulinotropic hormone and its construction method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100135141A CN100497591C (en) | 2005-05-16 | 2005-05-16 | Engineered bacteria Pichia pastoris for high yield of insulinotropic hormone and its construction method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1865430A CN1865430A (en) | 2006-11-22 |
| CN100497591C true CN100497591C (en) | 2009-06-10 |
Family
ID=37424577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100135141A Expired - Fee Related CN100497591C (en) | 2005-05-16 | 2005-05-16 | Engineered bacteria Pichia pastoris for high yield of insulinotropic hormone and its construction method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100497591C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109868281A (en) * | 2019-03-06 | 2019-06-11 | 江苏大学附属医院 | A method of Gluca Gen sample peptide -1 is expressed using bacillus subtilis |
| CN112725211A (en) * | 2020-12-18 | 2021-04-30 | 奥锐特药业(天津)有限公司 | Recombinant pichia pastoris, culture method and application |
-
2005
- 2005-05-16 CN CNB2005100135141A patent/CN100497591C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 重组人胰高血糖素样肽-1的表达、纯化及其生物学活性. 张志珍等.中国生物化学与分子生物学报，第18卷第1期. 2002 |
| 重组人胰高血糖素样肽-1的表达、纯化及其生物学活性. 张志珍等.中国生物化学与分子生物学报，第18卷第1期. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1865430A (en) | 2006-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101501209B (en) | A method of producing biologically active polypeptide having insulinotropic activity | |
| JP2662390B2 (en) | Insiulin analog | |
| Wang et al. | Human insulin from a precursor overexpressed in the methylotrophic yeast Pichia pastoris and a simple procedure for purifying the expression product | |
| JPH03143385A (en) | Yeast cell | |
| CN110724187B (en) | Recombinant engineering bacterium for efficiently expressing liraglutide precursor and application thereof | |
| US20230295594A1 (en) | Method for the efficient expression and purification and application of a recombinant fusion protein of mannase and homologues thereof and glp-1 | |
| CN111793126A (en) | Preparation method of GLP-1 analogue polypeptide and application thereof in type II diabetes | |
| CN109295067B (en) | Codon-optimized degummed insulin precursor gene and expression method thereof | |
| CN106939315B (en) | Preparation method and application of oxalate decarboxylase | |
| CN100497591C (en) | Engineered bacteria Pichia pastoris for high yield of insulinotropic hormone and its construction method | |
| EP0026598A1 (en) | DNA transfer vectors for human proinsulin and human pre-proinsulin, microorganisms transformed thereby, and processes involving such substances | |
| EP2831262B1 (en) | Secretion of functional insulin glargine directly into the culture medium through over expression of kex2p intracellularly | |
| Hou et al. | High-level expression of fusion protein containing 10 tandem repeated GLP-1 analogs in yeast Pichia pastoris and its biological activity in a diabetic rat model | |
| CN116554309A (en) | Recombinant human III type collagen and preparation method and application thereof | |
| US8691530B2 (en) | Process for obtaining aspart insulin using a Pichia pastoris yeast strain | |
| AU2019218315A1 (en) | Codon optimized precursor gene and signal peptide gene of human insulin analogue | |
| CN101280017A (en) | Fused protein of human brain natriuretic peptide diad [(BNP)2] and human serum albumin (HAS), and preparation thereof | |
| CN1873006A (en) | Method for producing recombined human proinsulin | |
| DE19943383B4 (en) | Regulatory sequences and expression cassettes for yeasts | |
| CN101824388A (en) | Yeast for dietary therapy of diabetes and construction method thereof | |
| CN1187451C (en) | Method of making proteins in transformed yeast cells | |
| CN113956989B (en) | Genetically engineered bacterium secreting urate oxidase, construction method and application thereof | |
| CN111560379B (en) | Codon-optimized insulin aspart precursor gene, recombinant vector, genetic engineering bacterium and application thereof | |
| CN102492716A (en) | Construction and using method of pichia pastoris expression vector facilitating achievement of natural N end expression of protein | |
| KR20240000403A (en) | A method for production of insulin using protein fusion technique in yeast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090610 Termination date: 20120516 |